Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF)
Assessment of the safety and tolerability of PLN-74809 following daily administration for up to 28 days in patients with idiopathic pulmonary fibrosis
Aged 50 years or older Idiopathic Pulmonary Fibrosis (IPF) diagnosis
Exclusion Criteria:
Receiving non-approved agents to treat IPF Need for continuous oxygen supplementation >15 hours/day Active lung or sinus infection Active smoker Hepatic impairment or end-stage liver disease